From Bloomberg:
On a rainy morning in February 2013 at Seattle Children’s Hospital, doctors and nurses were rushing in and out of the tiny room of a 5-year-old kidney cancer patient, Stellablue, who was getting a second round of aggressive chemotherapy following a relapse. Taking a break from the hectic atmosphere, her father, Andy Woods, headed to the hospital computer library with his other daughter, a toddler, on his shoulder. The first article he read that day described recent experiments in mice suggesting that a drug called IMGN901 could kill cells from Wilms tumor, Stellablue’s rare childhood disease. Woods, a bathroom and kitchen tile contractor from Bozeman, Montana, was becoming proficient in understanding medical papers. If Stellablue’s treatment failed again, he knew this could offer a potential option.